Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone in Mild Chronic Renal Failure (CRIB-II)
NCT00291720Phase 2Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Apr 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cardiovascular disease (CVD) comparing Spironolactone with Placebo (2 arms). Primary endpoints: Changes in left ventricular mass at 9 months and Arterial stiffness assessed by pulse wave velocity at 9 months. Started Apr 2005; status: completed.
02
Drugs
spironolactone
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00291720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291720.